Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.34 |
| ▸ | CYP21A2 | P08686 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002683 | 0.92 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL12602076 | 0.91 | EGLN1 (0.49) | EGLN1LTA4HALDH1A1HPGD | |
| SCHEMBL12014183 | 0.90 | EGLN1 (0.41) | EGLN1ADRB2ADRB1ADRB3LTA4H | |
| SCHEMBL12602154 | 0.89 | EGLN1 (0.41) | EGLN1ADRB2ADRB1ADRB3LTA4H | |
| SCHEMBL12002662 | 0.87 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL12014177 | 0.86 | EGLN1 (0.44) | EGLN1ADRB2ADRB1ADRB3CYP17A1 | |
| SCHEMBL12602041 | 0.86 | EGLN1 (0.48) | EGLN1ADRB2ADRB1ADRB3CYP17A1 | |
| SCHEMBL12602031 | 0.86 | HPGD (0.45) | EGLN1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL12602029 | 0.85 | EGLN1 (0.50) | EGLN1ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL27877548 | 0.85 | SYK (0.35) | EGLN1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | EPOR, EGLN2, EGLN1 | EGLN1 3/4885ADRB2 2080/4885ADRB1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.